文献速递骨软组织肉瘤与黑色素瘤

替本妥单抗采用逐步递增给药方案治疗转移性葡萄膜黑色素瘤的I期安全性、耐受性和疗效研究及扩展队列

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
PubMed 文献 · J Clin Oncol · 2022-03-07

这项开放标签、国际性I期/II期研究纳入HLA-A*02或HLA-A*02:01阳性的转移性葡萄膜黑色素瘤患者,采用三周逐步递增给药方案确定II期推荐剂量(RP2D),并评估安全性、药代动力学、药效动力学和初步临床活性。68 μg被确定为RP2D,总体缓解率为11.9%(95% CI,4.0至25.6),中位随访32.4个月时中位总生存期为25.5个月,1年总生存率为67%。逐步递增给药使RP2D较每周固定给药提高36%,副作用可控并显示疗效信号。

要点

  • 三周逐步递增给药(20-30-68 μg)确定的RP2D为68 μg,较每周固定给药提高36%。
  • 最常见治疗中出现的不良事件为发热(91%)、皮疹(83%)、瘙痒(83%)、恶心(74%)、疲乏(71%)和寒战(69%)。
  • 总体缓解率为11.9%(95% CI,4.0至25.6),中位总生存期为25.5个月,1年总生存率为67%。

核心结论

  • 采用替本妥单抗逐步递增给药方案使RP2D较每周固定给药提高36%,副作用可控并在转移性葡萄膜黑色素瘤中显示疗效信号。

研究设计与样本

  • 开放标签、国际性I期/II期研究,纳入HLA-A*02或HLA-A*02:01阳性的转移性葡萄膜黑色素瘤患者。
  • 第1周接受替本妥单抗20 μg一次,第2周30 μg一次,从第3周开始以54 μg起始按标准3+3设计进行剂量递增以确定RP2D。
  • 扩展阶段患者按RP2D(20-30-68 μg)治疗。
  • 2016年3月至2017年12月共入组42例符合条件的患者,既往治疗中位数为二线,其中剂量递增队列19例、初始剂量扩展队列23例。
  • 采集血液和肿瘤样本进行药代动力学/药效动力学评估,截至2017年12月对所有有基线疗效数据的患者评估治疗疗效。

主要发现

  • 在所研究的剂量水平中,68 μg被确定为RP2D。
  • 无论归因如何,最常见的治疗中出现的不良事件为发热(91%)、皮疹(83%)、瘙痒(83%)、恶心(74%)、疲乏(71%)和寒战(69%)。
  • 毒性在前三次给药后减轻。
  • 总体缓解率为11.9%(95% CI,4.0至25.6)。
  • 中位随访32.4个月时,中位总生存期为25.5个月(范围,0.89-31.1个月),1年总生存率为67%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week step-up dosing regimen, and to assess its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with metastatic uveal melanoma (mUM). METHODS: In this open-label, international, phase I/II study, HLA-A*02 or HLA-A*02:01+ patients with mUM received tebentafusp 20 μg once in week 1 and 30 μg once in week 2. Dose escalation (starting at 54 μg) began at week 3 in a standard 3 + 3 design to define RP2D. Expansion-phase patients were treated at the RP2D (20-30-68 μg). Blood and tumor samples were collected for pharmacokinetics/pharmacodynamics assessment, and treatment efficacy was evaluated for all patients with baseline efficacy data as of December 2017. RESULTS: Between March 2016 and December 2017, 42 eligible patients who failed a median of two previous treatments were enrolled: 19 in the dose escalation cohort and 23 in an initial dose expansion cohort. Of the dose levels investigated, 68 μg was identified as the RP2D. Most frequent treatment-emergent adverse events regardless of attribution were pyrexia (91%), rash (83%), pruritus (83%), nausea (74%), fatigue (71%), and chills (69%). Toxicity attenuated following the first three doses. The overall response rate was 11.9% (95% CI, 4.0 to 25.6). With a median follow-up of 32.4 months, median overall survival was 25.5 months (range, 0.89-31.1 months) and 1-year overall survival rate was 67%. Treatment was associated with increased tumor T-cell infiltration and transient increases in serum inflammatory mediators. CONCLUSION: Using a step-up dosing regimen of tebentafusp allowed a 36% increase in the RP2D compared with weekly fixed dosing, with a manageable side-effect profile and a signal of efficacy in mUM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Carvajal RD, Nathan P, Sacco JJ, et al. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol. 2022. PMID: 35254876. doi:10.1200/JCO.21.01805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。